BCG and cancer (first of two parts).

No abstract is available for this paper.

• Publication year

  2010

• Venue

  New England Journal of Medicine

• Publication date

  2010-01-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM197406202902506PMID 4364286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma.

  1974cited by this paper
• Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3.

  1974cited by this paper
• Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. IV. Development of immunity to tumor cells and BCG.

  1974cited by this paper
• Macrophage Nonimmunologic Recognition: Target Cell Factors Related to Contact Inhibition

  1973cited by this paper
• Comparative and combined effect of BCG and neuraminidase in experimental immunotherapy.

  1973cited by this paper
• A guinea pig model for tumor immunology. A summary.

  1973cited by this paper
• Effect of treatment of C57BL-6 mice with the methanol extraction residue fraction of BCG on leukemogenesis induced by the radiation leukemia virus.

  1973cited by this paper
• Immunopotentiation with BCG. I. Immune response to different strains and preparations.

  1973cited by this paper
• BCG immunotherapy of local subcutaneous growths and post‐surgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin

  1973cited by this paper
• Effect of Mycobacterium bovis BCG-Praha on the growth of transplanted Daels' sarcoma in guinea-pigs.

  1973cited by this paper
• BCG Immunotherapy of Pulmonary Growths from Intravenously Transferred Rat Tumour Cells

  1973cited by this paper
• Immunoprophylaxis of methylcholanthrene-induced tumors in mice with Bacillus Calmette-Guérin and methanol-extracted residue.

  1973cited by this paper
• Repetitive administration of BCG in prevention and treatment of spontaneous leukemia of AKR mice.

  1973cited by this paper
• BCG immunotherapy of rat tumors of defined immunogenicity.

  1973cited by this paper
• Studies of the effects of Bacillus Calmette-Guérin on Moloney sarcoma virus-induced tumors in normal and immunosuppressed mice.

  1973cited by this paper
• Tumor-specific, cell-mediated immunity in guinea pigs with tumors.

  1973cited by this paper
• Granulomatous Hypersensitivity to Trehalose-6,6′-Dimycolate (Cord Factor) in Mice Infected with BCG

  1973cited by this paper
• Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors.

  1973cited by this paper
• Bacillus Calmette-Guérin vaccination and skin tumor promotion with croton oil in mice.

  1973cited by this paper
• Effects of BCG on various facets of the immune response against polyoma tumors in rats

  1973cited by this paper
• An experimental model for immunotherapy of cancer.

  1973cited by this paper
• Tumor immunity induced by BCG-tumor cell mixtures in syngeneic mice.

  1973cited by this paper
• Migration Inhibitory Factor and Interferon in the Circulation of Mice with Delayed Hypersensitivity

  1973cited by this paper
• Mycobacterial cell wall components in tumor suppression and regression.

  1973cited by this paper
• Adjuvants for a tumor-specific vaccine: Bordetella pertussis or mycobacterial cell walls attached to oil droplets.

  1973cited by this paper
• Aryl hydrocarbon (benzo(alpha)pyrene) hydroxylase in guinea pig peritoneal macrophages: benz(alpha)anthracene-induced increase of enzyme activity in vivo and in cell culture.

  1973cited by this paper
• Effect of three strains of BCG against a murine leukemia after drug therapy.

  1973cited by this paper
• Protective effects of BCG and other bacteria against neoplasia in mice and hamsters.

  1973cited by this paper
• Tumor regression mediated by Mycobacterium bovis (strain BCG). Effects of isonicotinic acid hydrazide, cortisone acetate, and antithymocyte serum.

  1973cited by this paper
• Adjuvant preoperative and postoperative immunochemotherapy for mammary adenocarcinoma in rats.

  1973cited by this paper
• Effect of dose and route of Bacillus Calmette-Guérin in chemoimmunostimulation therapy of a murine leukemia.

  1973cited by this paper
• Regression of polyoma tumor metastasis by combined unblocking and bcg treatment‐correlation with induced alterations in tumor immunity status

  1973cited by this paper
• [Local intensification of cellular immunologic reactions and resistance to the development of tumors].

  1972cited by this paper
• Immunoprophylaxis and immunotherapy of leukaemia with B.C.G.

  1972cited by this paper
• Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy.

  1972cited by this paper
• Inhibitory effects of BCG on adenovirus tumorigenesis: Dependence on administration schedule

  1972cited by this paper
• Tumor suppression by cell walls of mycobacterium bovis attached to oil droplets.

  1972cited by this paper
• Tumor regression mediated by Mycobacterium bovis (strain BCG).

  1972cited by this paper
• Regression of spontaneous mammary carcinomas using direct injections of neuraminidase and BCG.

  1972cited by this paper
• Aryl Hydrocarbon (Benzopyrene) Hydroxylase Is Stimulated in Human Lymphocytes by Mitogens and Benz[a]anthracene

  1972cited by this paper
• Active immunotherapy of AkR mice spontaneous leukemia.

  1972cited by this paper
• Response of Syngeneic Murine Lymphomata to Immunotherapy in Relation to the Antigencity of the Tumour

  1972cited by this paper
• Immunospecific Regression of Methylcholanthrene Fibrosarcoma Using Neuraminidase: III. Synergistic Effect of BCG and Neuraminidase Treated Tumor Cells

  1972cited by this paper
• Tumour growth and non-specific immunity in rats: the mechanisms involved in inhibition of tumour growth.

  1972cited by this paper
• Combined chemoimmunostimulation therapy against murine leukemia.

  1972cited by this paper
• Effect of BCG on carcinogen-induced tumor development in mice.

  1972cited by this paper
• [BCG and experimental leukemia].

  1972cited by this paper
• Immunotherapy of Friend Disease in Mice Employing Viable BCG Vaccine 1

  1972cited by this paper
• Comparative effect of Mycobacterium bovis- and neuraminidase-treated tumor cells on the growth of established methylcholanthrene fibrosarcomas in syngeneic mice.

  1972cited by this paper
• Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis.

  1972cited by this paper
• Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis.

  1972cited by this paper
• Effect of BCG on Friend Disease Virus in Mice

  1971cited by this paper
• Leukemia L1210 therapy trials with antileukemia serum and Bacillus Calmette-Guérin.

  1971cited by this paper
• Combined use of BCG and neuraminidase in experimental tumor immunotherapy.

  1971cited by this paper
• Inhibition of murine sarcoma virus oncogenesis with living BCG

  1971cited by this paper
• Effect of Bacillus Calmette-Guérin on mammary tumor formation and cellular immunity in dimethylbenz(a)anthracene-treated rats.

  1971cited by this paper
• [Pseudowasting syndrome and carcinogenesis after 20-methylcholanthrene administration and effects of Mycobacterium Calmette-Guérin (BCG) in newborn and young mice].

  1971cited by this paper
• Attempts to prevent acquired immunological insufficiences in mice by Bacillus Calmette-Guérin

  1971cited by this paper
• Active immunotherapy of mouse RC 19 and E ♀ K1 leukaemias applied after the intravenous transplantation of the tumour cells

  1971cited by this paper
• Effects of Bacillus Calmette-Guérin (BCG) infection on residual disease of the rat mammary tumor after ovariectomy.

  1971cited by this paper
• Suppression of tumor growth and induction of specific tumor immunity by intradermal inoculation of a mixture of living tumor cells and live Mycobacterium bovis in syngeneic mice.

  1971cited by this paper
• Effects of active specific and non-specific immunotherapy on E male G2 leukemia according to the route of administration and combination of immunological stimulants.

  1971cited by this paper
• Immunotherapy of Cancer: Regression of Tumors after Intralesional Injection of Living Mycobacterium bovis

  1971cited by this paper
• Evidence for immunological surveillance during skin carcinogenesis. Inflammatory foci in immunologically competent mice.

  1971cited by this paper
• Immunotherapy of Cancer: Immunospecific Rejection of Tumors in Recipients of Neuraminidase-Treated Tumor Cells Plus BCG

  1971cited by this paper
• Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin.

  1971cited by this paper
• Suppression of Urethan-Induced Lung Adenomas in Mice Treated with Trehalose-6,6-Dimycolate (Cord Factor) and Living Bacillus Calmette Gu�rin

  1971cited by this paper
• [Influence of preceding immunization with BCG on growth of UVT tumors in mice].

  1971cited by this paper
• Stimulating influence of bacillus Calmette-Guérin on immunity to polyoma tumors and spontaneous leukemia.

  1971cited by this paper
• Immune Response to Sheep Red Blood Cells in Mice Pretreated with Mycobacterial Fractions

  1971cited by this paper
• Immunotherapy experiments with a methylcholanthrene-induced guinea pig liposarcoma.

  1971cited by this paper
• Influence of BCG infection on growth of 3-methylcholanthrene-induced rat sarcomas.

  1971cited by this paper
• Immunosurveillance and cancer.

  1970cited by this paper
• An experimental model of active immunotherapy preceded by cytoreductive chemotherapy.

  1970cited by this paper
• Facilitation of Rat Mammary Tumour Growth by BCG

  1970cited by this paper
• Tumor Immunity Produced by the Intradermal Inoculation of Living Tumor Cells and Living Mycobacterium bovis (Strain BCG)

  1970cited by this paper
• [Growth of solid Ehrlich ascites tumors in mice following BCG immunization].

  1969cited by this paper
• Role of the Immune System in the Growth of an Isotransplanted Urethan-Induced Lymphosarcoma

  1969cited by this paper
• Effect of BCG and Allogeneic Tumour Cells on Adenovirus Type 12 Tumorigenesis in Mice

  1969cited by this paper
• Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells.

  1969cited by this paper
• Immunologic surveillance at the marcoscopic level: nonselective elimination of premalignant skin papillomas.

  1969cited by this paper
• Immune status of the primary host toward its own methylcholanthrene-induced sarcomas.

  1968cited by this paper
• [Effects of B.C.G. on the hepatic catalase activity in mouse. Relation between the reticuloendothelial system and the resistance against grafted AKR leukemia].

  1968cited by this paper
• Evidence for the antigenicity of papillomas induced by 3-methylcholanthrene.

  1968cited by this paper
• [Effect of BCG on immunization induced by an isologous tumor in its originial strain and in F1 hybrids].

  1967cited by this paper
• Influence of bacille Calmette-Guérin infection on polyoma in hamsters and mice.

  1966cited by this paper
• Effect of bacillus Calmette-Guérin and/or methylcholanthrene on the antibody-forming cells measured at the cellular level by a hemolytic plaque test.

  1966cited by this paper
• [Action of a BCG inoculation in F1 hybrids of the phenomenon of syngenic preference demonstrated by certain isologous tumors].

  1966cited by this paper
• Inhibition of experimental leukaemia by a combination of various factors.

  1966cited by this paper
• STUDIES ON THE HETEROLOGOUS IMMUNOGENICITY OF A METHANOL-INSOLUBLE FRACTION OF ATTENUATED TUBERCLE BACILLI (BCG)

  1966cited by this paper
• Relation between tumor growth and host resistance.

  1965cited by this paper
• Suppression of strontium-90-induced development of bone tumors by infection with Bacillus Calmette-Guérin (BCG).

  1965cited by this paper
• [RELATIONSHIP BETWEEN CANCER AND TUBERCULOSIS. 2). A RETARDING EFFECT OF BCG INOCULATION FOR TUMOR INDUCTION IN MICE WITH INH OR URETHANE-4 NQO INJECTIONS].

  1964cited by this paper
• AN IMMUNOLOGICAL METHOD OF INCREASING THE SENSITIVITY OF PRIMARY SARCOMAS TO LOCAL IRRADIATION WITH X RAYS.

  1964cited by this paper
• Effect of BCG Infection on Leukemia and Polyoma in Mice and Hamsters.∗

  1962cited by this paper
• Effect of prior splenectomy on the growth of Sarcoma 180 in normal and Bacillus Calmette-Guérin infected mice

  1962cited by this paper
• [Relationship between cancer and tuberculosis. 1. Effect of tubercle bacilli infection on transplanted tumors in the mouse].

  1962cited by this paper
• [Stimulation of the reticuloendothelial system and development of experimental malignant tumors].

  1962cited by this paper
• Protective Activity of Fractions of Tubercle Bacilli against Isologous Tumours in Mice

  1961cited by this paper
• The role of the reticuloendothelial system in the host reaction to neoplasia.

  1961cited by this paper

• IL-15: from discovery to FDA approval

  2025cites this paper
• The past, present, and future of immunotherapy for colorectal cancer

  2023cites this paper
• A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment.

  2021cites this paper
• BCG: a vaccine with multiple faces

  2020cites this paper
• Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.

  2018cites this paper
• Cancer immunotherapy: Breakthrough or “deja vu, all over again”?

  2017cites this paper
• Active (Patient Specific) Immunotherapy of Colon Cancer: A Transition from Preclinical Studies to Successful Clinical Trials

  2014cites this paper
• Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.

  2013cites this paper
• Role of the systemic immune system in brain metastasis.

  2013cites this paper
• The Role and Regulation of p53-associated, Parkin-like Cytoplasmic Protein (PARC) in p53 Subcellular Trafficking and Chemosensitivity in Human Ovarian Cancer Cells

  2012cites this paper
• Cancer immunotherapy.

  2011cites this paper
• Calpain-mediated Processing of p53-associated Parkin-like Cytoplasmic Protein (PARC) Affects Chemosensitivity of Human Ovarian Cancer Cells by Promoting p53 Subcellular Trafficking*

  2011cites this paper
• Role of endogenous biological response modifiers in pathogenesis of infectious diseases.

  2011cites this paper
• Treatment of periocular equine sarcoids

  2010cites this paper
• Adjuvant properties of a simplified C32 monomycolyl glycerol analogue.

  2009cites this paper
• [Postoperative immunostimulation in non-small-cell bronchial carcinoma. Outcome and complications].

  2008cites this paper
• Abnormal variation of the immune response as related to cancer

  2008cites this paper
• Preparation and Characterization of Agonistic Monoclonal Antibodies Against Toll-Like Receptor 4-MD-2 Complex

  2007cites this paper
• Adjuvante Therapie des Melanoms

  2006cites this paper
• Acute and subacute toxicity of chemotactic conjugates between monoclonal antibody and fMet-Leu-Phe in humans: A phase I clinical trial

  2005cites this paper
• Henoch-Schönlein purpura after intravesical administration of bacillus Calmette-Guérin

  2005cites this paper
• The immunopathological effects of intracolonic injection of Mycobacterium bovis BCG cell wall emulsions in guinea pigs

  2004cites this paper
• therapeutic vaccines for colorectal cancer

  2004cites this paper
• Human tumor-associated antigens identified by monoclonal antibodies

  2004cites this paper
• Post-operative intrapleural BCG in lung cancer: A 5-year follow-up report

  2004cites this paper
• Síndrome de Reiter recidivante después de inmunoterapia con Bacillus Calmette-Guérin para el carcinoma de vejiga

  2003cites this paper
• [Relapsing Reiter's syndrome after Bacillus Calmette-Guérin immunotherapy for bladder carcinoma].

  2003cites this paper
• Structural-functional relationship of pathogen-associated molecular patterns: lessons from BCG cell wall skeleton and mycoplasma lipoprotein M161Ag.

  2002cites this paper
• Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression

  2002cites this paper
• T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.

  2001cites this paper
• Development of immunoadjuvants for immunotherapy of cancer.

  2001cites this paper
• BCG vaccination to prevent implantation of endometriosis: an experimental study in rats.

  2001cites this paper
• Oligodeoxyribonucleotides with 5'-ACGT-3' or 5'-TCGA-3' sequence induce production of interferons.

  2000cites this paper
• [Adjuvant drug therapy of malignant melanoma. Current knowledge and multi-center studies in German-speaking countries].

  2000cites this paper
• CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.

  2000cites this paper
• Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.

  2000cites this paper
• Adjuvante Interferontherapie des Melanoms

  2000cites this paper
• Case of the season. Miliary pulmonary granulomatous disease. Secondary to BCG immunotherapy.

  1999cites this paper
• Case of the season

  1999cites this paper
• How BCG led to the discovery of immunostimulatory DNA.

  1999cites this paper
• BCG’s Mechanism of Action – Increasing our Understanding

  1999cites this paper
• Updated concepts and treatment of carcinoma in situ.

  1998cites this paper
• Die adjuvante und neoadjuvante Therapie des Melanoms

  1998cites this paper
• Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?

  1998cites this paper
• Equine sarcoids.

  1998cites this paper
• Dermatologic tumors (excluding sarcoids).

  1998cites this paper
• Disseminated pulmonary granulomas after intravesical bacillus Calmette-Guérin immunotherapy.

  1997cites this paper
• Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group.

  1997cites this paper
• Adjuvant Melanoma Therapy

  1997cites this paper
• Immunotherapy of bladder cancer.

  1997cites this paper
• Tumor immunology.

  1997cites this paper
• Adjuvant therapy for cutaneous malignant melanoma.

  1997cites this paper
• The role of immunotherapy in urologic malignancies.

  1996cites this paper
• Cell-mediated-immunity and immunotherapy in ovarian-cancer (review).

  1995cites this paper
• Infection of a ruptured aortic aneurysm and an aortic graft with bacille Calmette-Guérin after intravesical administration for bladder cancer.

  1995cites this paper
• Immunotherapy of Superficial Bladder Cancer

  1994cites this paper
• BCG in der Immuntherapie von Tumoren — Eine kurze historische Übersicht

  1994cites this paper
• Mycobacteriosis and Nocardiosis in the Immunocompromised Host

  1994cites this paper
• Intravesical Evans bacille Calmette-Guérin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group.

  1994cites this paper
• Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside

  1994cites this paper
• The Mycobacterium bovis BCG 64-kDa surface protein is antigenically shared with different mouse tumor cells and has anti-tumor activity in immunized mice.

  1993cites this paper
• Immunotherapy and Immunopotentiation

  1993cites this paper
• Report of the first international workshop on equine sarcoid.

  1993cites this paper
• Ist die Behandlung mit BCG eine Immuntherapie

  1993cites this paper
• BCG in the treatment of superficial cancer of the bladder: A review

  1993cites this paper
• Psoas abscess following intravesical bacillus Calmette-Guerin for bladder cancer: a case report.

  1993cites this paper
• Principles of intravesical chemotherapy and immunotherapy.

  1992cites this paper
• Tumoren des Urogenitaltraktes

  1992cites this paper
• Immunotherapy of breast cancer.

  1992cites this paper
• Carcinoma in situ.

  1992cites this paper
• Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

  1992cites this paper
• Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall.

  1992cites this paper
• Experimental trials of immunotherapy for malignant melanoma.

  1991cites this paper
• Characterization of cellular infiltrates in the rat urinary bladder following BCG and thiotepa intravesical therapy

  1991cites this paper
• Effects of recombinant human interferon alpha on aryl hydrocarbon hydroxylase activity in cultured human peripheral lymphocytes.

  1991cites this paper
• Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin.

  1990cites this paper
• [Intravesical BCG as a treatment for superficial and in situ transitional cell carcinoma of the bladder].

  1990cites this paper
• Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.

  1990cites this paper
• Therapy for cutaneous melanoma: an update.

  1990cites this paper
• Immunotherapy and Biological Therapy of Cancer

  1990cites this paper
• Biological-response modifier--induced emergencies.

  1989cites this paper
• Abnormal Variation of the Immune System as Related to Cancer

  1989cites this paper
• Suppressor Cells in Mycobacterial Infections

  1988cites this paper
• Triggering of a Cytolytic Factor with TNF-Like Activity From Human Monocytes

  1988cites this paper
• Disseminated granulomatous disease (BCGosis) following chemoimmunotherapy for ovarian carcinoma.

  1988cites this paper
• Heutiger Stand der adjuvanten Therapie

  1988cites this paper
• Loco-regional recurrent melanoma: II. Non-systemic treatments (1964-1979).

  1988cites this paper
• Mycobacterial and Nocardial Infections in the Compromised Host

  1988cites this paper
• [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].

  1987cites this paper
• Immunology of Malignant Diseases

  1987cites this paper
• Histopathology of BCG and thiotepa treated bladders

  1987cites this paper
• Clinical observations on the use of BCG cell wall fraction for treatment of periocular and other equine sarcoids

  1987cites this paper
• BCG immunotherapy for superficial bladder cancer

  1987cites this paper
• The Evolution of Mycobacterial Disease in Human Populations: A Reevaluation [and Comments and Reply]

  1987cites this paper
• Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG

  1987cites this paper
• Manipulation of the intratumor infiltrate by anti-tumor antibody conjugates.

  1987cites this paper
• Biologic response modifiers in genitourinary neoplasia

  1987cites this paper
• Evidence for macrophage involvement in the enhancement of tumor growth delay with X-ray/Fluosol-DAR/O2 combination therapy.

  1987cites this paper
• Immunobiology of Human Breast Cancer

  1987cites this paper
• Biologic response modifiers as adjuncts to other therapeutic modalities.

  1986cites this paper